Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

01 Feb 2018

2406.30

-0.76%

Ajanta Pharma

Hold: Ajanta Pharma Ltd.

SPA Research

Ajanta Pharma reported a 10% YoY growth in revenues for the quarter driven by ~80% YoY growth in Asian sales to INR 1610 million. The US sales saw a growth of ~20% YoY during the quarter to INR 710 million. The company believes the severity of the pricing pressure to have reduced substantially in the US. The company maintained its EBITDA margins YoY at 33.6%,...

Ajanta Pharma Ltd. has an average target of 3051.67 from 6 brokers.

Ajanta Pharma Ltd.

30 Jan 2018, 12:00AM

2406.30

-0.76%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 10% YoY to | 587 crore (I-direct estimate: | 553 crore) mainly due to 15% growth in export formulations, led by 79% growth in the Asia business to | 161 crore and ~20% growth in the US to | 71 crore. Domestic sales grew 4% YoY to | 155 crore EBITDA margins improved 36 bps YoY to 33.6% (I-direct estimate: 33.5%) mainly due to an improvement in gross margins by 123 bps YoY to 81.3%. EBITDA increased 11% YoY to | 198 crore...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

20 Dec 2017

2406.30

-0.76%

Ajanta Pharma: Expect improvement from FY19 after a trough this year

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Inventory has been gradually restoring post GST roll-out from very low levels,and the streamlining of supply-side system is leading to sustained better off-take in domestic formulation (DF). A JP is building a facility at Guwahati to reduce outsourcing, and thus, ensure better administrative control/compliance and also enjoy tax benefits. Although only five ANDAs were filed for the US market in 1HFY18, the company has maintained its guidance of 10-15 filings over FY18. After declining sharply in 2QFY18, US sales are expected to pick up, l ed by the launch of recently approved products and increased traction in existing products.AJP has been selected as a supplier in the institutional anti-malaria business from the Global Fund, but is yet to obtain orders. The company maintained its guidance of 15-20 % YoY lower sales in FY18 due to lower allocation from the Global Fund.

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

07 Nov 2017

2406.30

-0.76%

Fundamental Research Report : Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Choice India

Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and Institutional sales. The branded generics business is spread in India and over 30 emerging countries across Africa, Commonwealth of Independent States (CIS), the Middle East and South East Asia. Company's Institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa....

Ajanta Pharma Ltd. has lost -27.80% in the last 1 Year

Ajanta Pharma Ltd.

01 Nov 2017

2406.30

-0.76%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 5% YoY at | 540 crore (I-direct estimate: | 506 crore) mainly due to 13% YoY growth in domestic sales to | 178 crore (Idirect estimate: | 173 crore). Export formulations grew marginally by 1% to | 350 crore (I-direct estimate: | 317 crore) EBITDA margins increased 51 bps YoY to 34% (I-direct estimate: 29.1%). Improvement in gross margins by 242 bps YoY to 80% was largely offset by 256 bps increase in employee expenses to 16.5% Adjusted net profit remained flat YoY at | 132 crore (I-direct...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Nov 2017

2406.30

-0.76%

Ajanta Pharma - 2QFY18 Result Update

Buy: Ajanta Pharma Ltd.

Reliance Securities

Growth Momentum to Continue in Domestic Biz; Maintain BUY Led by recovery in domestic formulations business and robust performance in African business, Ajanta Pharma (AJP) has delivered a better-than-expected performance in 2QFY18. Its revenues, EBITDA and PAT stood at Rs 5.4bn (vs. our estimate of Rs 4.8bn), Rs 1.8bn (vs. our estimate of Rs 1.4bn) and Rs 1.3bn (vs. our estimate of Rs 1.0bn), respectively. EBITDA margin at 34.0% exceeded our estimate of 29.0% led by better product-mix and recovery in domestic business. Notably, AJP's US sales dipped 63% YoY to Rs260mn primarily owing to price erosion in base business product portfolio following channel consolidation. Notably, AJP plans to file 12-15 ANDAs with...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

31 Oct 2017, 12:00AM

2406.30

-0.76%

Ajanta Pharma: Strong 2Q; stance remains positive

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma's (AJP) 2QFY18 financial performance was better than expectations, with sales at INR5.4b (est. of INR5b), EBITDA margin at 34% (est. of 29%) and PAT at INR1.3b (est. of INR1b). DF and Africa drive growth: Sales grew 4.8% YoY, led by strong institutional anti-malaria sales and a recovery in domestic formulation (DF) business. However, a decline in US sales and moderate growth in Asia sales adversely affected overall sales growth for the quarter. Superior product mix and higher operating leverage led to 40bp YoY (+640bp QoQ) expansion in EBITDA margin....

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

12 Oct 2017

2406.30

-0.76%

Ajanta Pharma: Global Fund allocation to drive anti-malaria business

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Global Fund a key provider of insti-AM business Tender award by the Global Fund holds immense significance in the insti-AM segment. Notably, the Global Fund was the biggest contributor, with ~28% share in total funding to agencies in 2015. The Global Fund spent ~USD9.9b over 2005-17, which was utilized for 1) improving health systems (~59% of total spending), 2) prevention (~24%) and 3) treatment (~17%). The spending for treatment in 2016 is estimated at USD154m. Although the amount committed for 2017-19 is stable compared to that in 2014-16, the business for pharma companies will be...

Ajanta Pharma Ltd. has lost -27.80% in the last 1 Year

Ajanta Pharma Ltd.

10 Aug 2017

2406.30

-0.76%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Revenues remained flat YoY at | 473 crore (I-direct estimate: | 486 crore). Domestic growth was impacted by GST transition while export formulation growth was driven by robust growth in the US EBITDA margins declined 802 bps YoY to 26.8% (I-direct estimate: 31%) mainly due to the impact of GST transition and higher fixed overheads due to commissioning of new plants Adjusted net profit declined 21% YoY to | 95 crore (I-direct estimates: | 100 crore). Lower tax rate (20% against 24% in Q1FY17)...